BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 30959004)

  • 21. The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment.
    Hong IH; Choi W; Han JR
    Jpn J Ophthalmol; 2020 Mar; 64(2):196-202. PubMed ID: 31900869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
    Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ranibizumab Alters Levels of Intraocular Soluble Cytokine Receptors in Patients with Diabetic Macular Edema.
    Coughlin BA; Guha-Niyogi P; Sikorskii A; Glazer LC; Mohr S
    Curr Eye Res; 2020 Apr; 45(4):509-520. PubMed ID: 31488015
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of ranibizumab on growth factors and mediators of inflammation in the aqueous humor of patients with diabetic macular edema.
    Utsumi T; Noma H; Yasuda K; Goto H; Shimura M
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2597-2603. PubMed ID: 33772356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy.
    Mikhail M; Stewart S; Seow F; Hogg R; Lois N
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1411-1418. PubMed ID: 29779188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of ganglion cell layer cysts in diabetic macular oedema treated with anti-vascular endothelial growth factor.
    Ceklic L; Huf W; Ebneter A; Wolf S; Zinkernagel MS; Munk MR
    Acta Ophthalmol; 2019 Dec; 97(8):e1041-e1047. PubMed ID: 31099498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema.
    Eriş E; Perente I; Vural E; Vural A; Seymen Z; Celebi ARC; Erdogan G; Ozkaya A; Artunay O
    Int Ophthalmol; 2019 Jul; 39(7):1575-1580. PubMed ID: 29943100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
    Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
    Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.
    Hu Y; Wu Q; Liu B; Cao D; Dong X; Zhang L; Li T; Yang X; Yu H
    Graefes Arch Clin Exp Ophthalmol; 2019 Dec; 257(12):2613-2621. PubMed ID: 31529324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
    Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
    Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema.
    Cicinelli MV; Cavalleri M; Querques L; Rabiolo A; Bandello F; Querques G
    Br J Ophthalmol; 2017 Dec; 101(12):1689-1693. PubMed ID: 28432109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF.
    Chang CK; Cheng CK; Peng CH
    Eye (Lond); 2017 May; 31(5):762-770. PubMed ID: 28106889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial.
    Fickweiler W; Klaassen I; Vogels IM; Hooymans JM; Wolffenbuttel BH; Los LI; Schlingemann RO;
    Invest Ophthalmol Vis Sci; 2016 Nov; 57(14):6234-6241. PubMed ID: 27842163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
    Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
    Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AQUEOUS HUMOR CYTOKINE LEVELS AS BIOMARKERS OF DISEASE SEVERITY IN DIABETIC MACULAR EDEMA.
    Hillier RJ; Ojaimi E; Wong DT; Mak MY; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    Retina; 2017 Apr; 37(4):761-769. PubMed ID: 27471825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six-month changes in cytokine levels after intravitreal bevacizumab injection for diabetic macular oedema and macular oedema due to central retinal vein occlusion.
    Wen J; Jiang Y; Zheng X; Zhou Y
    Br J Ophthalmol; 2015 Oct; 99(10):1334-40. PubMed ID: 25841235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of antivascular endothelial growth factor treatment for diabetic macular oedema: a four-year real-world study.
    Granstam E; Rosenblad A; Modher Raghib A; Granström T; Eriksson JW; Lindholm Olinder A; Leksell J
    Acta Ophthalmol; 2020 Jun; 98(4):360-367. PubMed ID: 31656056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response.
    Lee J; Moon BG; Cho AR; Yoon YH
    Ophthalmology; 2016 Nov; 123(11):2368-2375. PubMed ID: 27613201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.